NVAX Stock Climbs As Partnership Model Keeps COVID Vaccine Cash Flow Open
Novavax said Sanofi and Takeda received clearances for an updated Nuvaxovid formulation for the 2026-2027 COVID season. Nuvaxovid is a protein-based, non-mRNA vaccine stored at standard fridge temperatures. The approvals allow Novavax to continue collecting royalties on partner sales in those markets. Sanofi commercializes Nuvaxovid in most major markets, while Takeda sells the shot in … Read more